sFas: a new warning signal in kidney disease?

By Ana Espino | Published on April 2, 2026 | 2 min read


Kidney dysfunction, whether acute (AKI) or chronic (CKD), represents a major public health issue. It is characterized by the progressive accumulation of uremic solutes and persistent systemic inflammation—two closely linked mechanisms involved in disease progression and the development of complications, particularly cardiovascular ones.  

Current diagnostic tools, especially serum creatinine, remain insufficient to capture the complexity of the underlying mechanisms. They fail to fully integrate the interplay between inflammation, apoptosis, and cellular dysfunction, which are central to renal pathophysiology.  

In this context, soluble Fas (sFas)—the circulating form of the CD95 receptor involved in apoptosis regulation—has gained increasing attention. Its potential role in modulating inflammatory responses and in the progression of kidney damage makes it a promising biomarker candidate.  

However, its exact role in kidney dysfunction remains to be clarified. This study, published in 2026 in the Brazilian Journal of Nephrology, aimed to analyze the association between sFas, inflammatory markers, and renal function, in order to assess its clinical relevance and potential as an integrated biomarker.  

Does sFas truly reflect renal severity?  

The authors conducted a systematic review and meta-analysis including 24 observational studies (13 cohort and 11 cross-sectional), with quantitative synthesis focused on 8 comparable cohorts.  

A total of 1,449 patients with kidney dysfunction were included. The data show a clear elevation of biomarkers in these patients, with mean creatinine levels of 2.8 mg/dL compared to 0.7 mg/dL in individuals without kidney disease. Consistently, levels of sFas (8,635 vs 3,206 pg/mL) and IL-6 (193.4 vs 29.7 pg/mL) were significantly higher, reflecting an enhanced inflammatory state. Quantitative analysis confirmed this trend. The meta-analysis demonstrated a significant association between sFas levels and kidney dysfunction, with moderate heterogeneity, as illustrated in the forest plot.  

Beyond this association, the results revealed consistent positive correlations between sFas, creatinine, and IL-6, highlighting the close interplay between impaired renal function and systemic inflammation. A significant relationship was also observed between sFas and C-reactive protein (CRP) (OR = 0.72; p = 0.001), although based on a limited number of studies.  

Overall, these findings suggest that sFas may act as a true biological reflection of kidney dysfunction, integrating both uremic retention and inflammatory activation mechanisms.   

A promising biomarker, still to be confirmed  

Kidney dysfunction is a complex condition characterized by chronic inflammation and progressive accumulation of uremic toxins, with interactions that remain incompletely understood. In this context, identifying reliable and integrative biomarkers is a major clinical challenge.  

This study aimed to evaluate the role of sFas within these mechanisms. The results show that elevated sFas levels are significantly associated with kidney dysfunction and inflammatory markers, suggesting its involvement in underlying pathophysiological processes.  

However, interpretation of these findings is limited by methodological heterogeneity, a limited number of studies for certain biomarkers—particularly IL-6—and the absence of analyses stratified by renal phenotypes.  

Although further large-scale prospective studies are needed, these findings highlight the potential of sFas as an integrated biomarker at the intersection of inflammation and uremic retention. In the future, its use could contribute to more refined risk stratification and improved therapeutic strategies in nephrology.